Bottom line
Is FPHAX a good fund? The bottom line
FPHAX is an actively managed health care sector mutual fund from Fidelity.
It charges 0.67% — about $67 a year on every $10,000 invested, cheaper than 72% of health care sector funds we track.
It returned +30.3% over one year, +12.6% a year over five years, +10.0% a year over ten (as of Apr 30, 2026, per its prospectus).
With $1.5 billion in net assets and 57 holdings, its largest position is ELI LILLY and CO (28.8%) and the top 10 make up 73.8% of the portfolio.
What stands out
- 5-year return beat 98% of category peers
What to watch
- Concentrated: top 10 holdings are 73.8% of assets
Updated Nov 19, 2026
What FPHAX invests in
Pharmaceuticals Portfolio seeks capital appreciation.
Normally investing at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. These companies may include, for example, pharmaceutical companies and other companies involved in the research, development, manufacture, sale, or distribution of drugs, including companies that facilitate the testing or regulatory approval of drugs, including veterinary drugs. For purposes of the fund's policy to normally invest at least 80% of its assets in securities of companies principally engaged in the business activity or activities identified for the fund, Fidelity may consider a company to be principally engaged in the designated business activity or activities based on: (i) the level of a company's assets, income, sales, or profits that are committed to, derived from, or related to the designated business…
From the fund's prospectus (filed Apr 24, 2026).
FPHAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FPHAX | +30.3% | +12.6% | +10.0% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Apr 30, 2026
What FPHAX costs
On a $10,000 investment, FPHAX's 0.67% expense ratio costs about $67 a year. The prospectus estimates $835 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
FPHAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | ELI LILLY and CO | 28.78% |
| 2 | Gsk Plc | 8.17% |
| 3 | Viatris Inc | 5.45% |
| 4 | Ucb Sa | 5.09% |
| 5 | MERCK and CO INC | 4.74% |
| 6 | Roche Holding Ag | 4.54% |
| 7 | Legend Biotech Corp | 4.53% |
| 8 | Astrazeneca Plc | 4.22% |
| 9 | Elanco Animal Health Inc | 4.15% |
| 10 | Jazz Pharmaceuticals Plc | 4.09% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 73.8% of the fund. See all top 25 holdings and asset mix →